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Previewswas 10-fold less potent for Vps34
(450 nM) but 1000-fold less potent for
p110g (4,428nM) giving a 10-fold selec-
tivity in favor of Vps34. At this stage there
are no structural data confirming the
binding mode of PT210 in Vps34 or
p110g, but the results suggest that even
more potent and selective inhibitors may
be within reach.
So how might such emerging inhibitors
be used? First, they could be employed
as improved tools to ask outstanding
questions about the precise roles of
Vps34 in cells. With respect to therapy,
since autophagy is a double-edged sword
in cancer (White and DiPaola, 2009) the
jury is still out as to whether inhibiting
autophagy would be a good or a bad
thing. The potential therapeutic effects of
pharmacologic Vps34 modulation may
well be context-dependent, and thus
there could perhaps be a need for bio-
markers for patient selection. Improved
Vps34 inhibitors would allow us to deter-
mine in a better way than before whether
it is time for the newly unveiled ancestral
PI3K to join some of the upstart younger
generation as a new cancer drug target.Furthermore, the recent emergence of
GOLPH3 as an oncoprotein involved in
vesicular trafficking (Scott and Chin,
2010) suggests that this area might be of
broader therapeutic significance, giving
rise to an even more extended target
family.
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Mutations in BRCA1 predispose to tumorigenesis presumably from the inability to accurately repair DNA
double-strand breaks by homologous recombination. Two new papers shed light on how loss of the DNA
damage response protein 53BP1 reverses phenotypes of BRCA1mutant cells, with potential clinical implica-
tions.Defects in homologous recombination
(HR) cause chromosome instability and
are associated with tumor predisposition
(Moynahan and Jasin, 2010). The inability
to accurately repair DNA double-strand
breaks (DSBs) by HR ultimately forces
cells to rely on alternative nontemplate-
based repair pathways, including nonho-
mologous end joining (NHEJ), resultingin the accumulation of chromosome aber-
rations, a hallmark of tumor cells. BRCA1,
mutations of which are associated with
a markedly increased risk of breast and
ovarian cancer, was the first tumor sup-
pressor gene identified to have an impor-
tant role in HR.
Recently, a surprising observation was
reported for mice deficient in BRCA1and the DNA damage response protein
53BP1, in that loss of 53BP1 rescued
the embryonic lethality, tumor suscepti-
bility, and premature aging of mice homo-
zygous forBrca1 exon 11 deletion without
fully eliminating the chromosome insta-
bility (Cao et al., 2009). Although defi-
ciency of other DNA damage response
factors such as p53 and Chk2 hadl 17, May 18, 2010 ª2010 Elsevier Inc. 423
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Previewspreviously been reported to rescue the
lethality of Brca1D11/D11 mice, tumorigen-
esis was nonetheless observed on these
backgrounds. Two new papers pursue
the protective mechanism imparted by
53BP1 loss in BRCA1 mutant cells and
explore its potential therapeutic implica-
tions.
In the April 16th issue of Cell, Bunting
and colleagues provide evidence for the
restoration of error-free homology-
directed repair in Brca1D11/D11 mouse
cells by deletion of 53BP1. Previous
work had indicated that 53BP1 promotes
NHEJ while suppressing HR, probably
mediated by its interaction with dimethy-
lated lysine 20 of histone H4 (Xie et al.,
2007). When 53BP1 is inhibited, the
normal competition between the two
prominent DSB repair pathways (Moyna-
han and Jasin, 2010) is disrupted and cells
have increased HR. In the new report,
53BP1 deficiency in Brca1D11/D11 B cells
is shown to result in a reduction in sponta-
neous and induced asymmetric radial
chromosome structures, which are char-
acteristic of HR deficiency and require
NHEJ to form (Bunting et al., 2010).
Importantly, the reduction in radials is
also seen upon treatment with an inhibitor
of the single-strand break repair protein
poly(ADP-ribose) polymerase (PARP).
PARP inhibitors selectively kill cells that
are deficient in HR and are currently being
used in clinical trials to treat cancer
patients with BRCA1 or BRCA2 mutation
(Rouleau et al., 2010). Bunting et al.
observed that 53BP1 loss renders
Brca1D11/D11 cells insensitive to PARP
inhibitor-induced cell death.
In a complementary paper recently
published in Nature Structural and Molec-
ular Biology, Bouwman and colleagues
provide evidence that 53BP1 loss rescues
phenotypes of cells completely devoid of
BRCA1 (Bouwman et al., 2010). Utilizing
a transposon-based insertional mutagen-
esis screen in conjunction with a select-
able Brca1 conditional allele, they
identified 53BP1 as a suppressor of the
proliferation defect of Brca1 null mouse
cells. Depletion of 53BP1 also reduced,
although did not eliminate, chromosome
aberrations and reversed cisplatin sensi-
tivity induced by Brca1 inactivation,
consistent with a restoration of HR profi-
ciency. Further, Bouwman and col-
leagues found that 53BP1 depletion
reduced checkpoint activation elicited424 Cancer Cell 17, May 18, 2010 ª2010 Elsby unrepaired DNA damage resulting
from Brca1 inactivation.
How might 53BP1 disruption restore
HR levels in BRCA1-deficient cells? The
central step in HR is DNA strand ex-
change catalyzed by the Rad51 protein.
Because Rad51 functions by forming
a nucleoprotein filament with single-
stranded DNA, a critical, early step of
HR is DNA end resection for single-
stranded DNA generation (Moynahan
and Jasin, 2010). Whereas BRCA2,
Rad51 paralogs, and other proteins are
thought to promote Rad51 nucleoprotein
filament formation, BRCA1 is implicated
in an upstream step of HR, possibly end
resection itself, because BRCA1 pro-
motes other repair pathways with single-
stranded DNA intermediates (Stark et al.,
2004). Bunting et al. provide evidence that
53BP1 suppresses end resection: during
resection, RPA loads onto the single-
stranded DNA and is phosphorylated;
deletion of 53BP1 dramatically increases
RPA phosphorylation.
A prediction of this model is that,
whereas loss of 53BP1 would rescue
defects in homology-directed repair in
Brca1 mutant cells, its absence would
not rescue cells with mutations in down-
stream HR genes. Both groups ad-
dressed this point, Bouwman et al. with
Brca2 mutation and Bunting et al. with
mutation of a Rad51 paralog gene,
Xrcc2, and found that 53BP1 loss has no
effect on either of these downstream
mutations as predicted. In general,
NHEJ components suppress HR, and
evidence suggests that this may be
through inhibition of end resection (Moy-
nahan and Jasin, 2010). Nonetheless,
unlike 53BP1, loss of the NHEJ compo-
nent Lig4 does not abrogate the PARP
inhibitor-induced radial chromosomes or
cell death of Brca1D11/D11 cells, indicating
a specific role for 53BP1 (Bunting et al.,
2010).
Given that 53BP1 loss is associated
with increased end resection as mea-
sured by RPA phosphorylation and that
ATM kinase activity has been shown to
promote end resection (Jazayeri et al.,
2006), Bunting et al. decided to examine
the effects of ATM inhibition. Chemical
inhibition of ATM resulted in decreased
RPA phosphorylation, reduced Rad51
foci formation after ionizing radiation, and,
significantly, resensitized Brca1D11/D11
53BP1/ cells to the antiproliferativeevier Inc.effects of PARP inhibition, suggesting a
critical role for ATM in promoting HR after
loss of 53BP1.
Besides mechanistic insights, both
studies have potentially intriguing thera-
peutic implications. Breast cancers
arising in BRCA1 mutation carriers are
often high grade, lack expression of both
estrogen and progesterone receptors,
and do not overexpress ERBB2/HER2,
hence are often referred to as triple-nega-
tive breast cancers. An analysis of breast
tumor samples from two independent
cohorts showed a significant association
between triple-negative breast tumors
and low levels of 53BP1 expression
(Bouwman et al., 2010). Furthermore,
tumors from BRCA1/2 mutation carriers
frequently showed reduced 53BP1 stain-
ing as compared to non-BRCA1/2
tumors. The decrease in 53BP1 may be
clinically important given that patients
with triple-negative breast tumors that
demonstrated low 53BP1 staining had
decreased survival.
Resistance to platinum-based chemo-
therapeutic agents is not uncommon in
ovarian tumors with BRCA1 mutations
and may be mediated in part by sec-
ondary mutations that restore function of
the BRCA1 protein (Swisher et al., 2008).
Based on the resistance to both crosslink-
ing agents and PARP inhibition presented
in these papers for mouse cells, loss of
53BP1 may be an alternative mechanism
by which BRCA1 tumors in patients
develop resistance to therapy. In light of
their findings, Bunting et al. suggest new
areas for therapeutic investigation, in-
cluding use of an ATM inhibitor in combi-
nation with a PARP inhibitor for resistant
tumors (Bunting et al., 2010). ATM defi-
ciency is already known to significantly
associate with triple-negative and
BRCA1/2 breast tumors in one of the
cohorts examined for 53BP1 (Tommiska
et al., 2008). It would be of interest to
ascertain whether the breast tumors that
show 53BP1 loss also demonstrate ATM
loss or whether these are mutually exclu-
sive, as would be necessary for the
combination therapy to be beneficial.
In summary, these new studies shed
light on a potential mechanism by which
loss of 53BP1 allows cells lacking func-
tional BRCA1 to overcome defects in HR
and hypersensitivity to various DNA-
damaging agents and provide convincing
evidence that 53BP1may be an important
Cancer Cell
Previewspharmacological target for future breast
cancer therapies.
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